Sacyr SA (0OFU)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 4.006 |
|---|---|
| 52-week range | 3.464 – 4.982 |
| Return, 1 month / 3 months | −4.3% / −16.2% |
| Return, 1 year / 3 years | +5.3% / +67.1% |
| Trend | Below its 200-day average |
| RSI (14) | 47 |
| Volatility (1 year) | 25.6% |
| Worst drawdown (1 year) | -21.5% |
| Average daily value traded | 1.73M EUR |
| Dividend yield | 3.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sacyr is a Spanish construction and infrastructure group based in Madrid. It designs and builds civil works such as roads, motorways, bridges and water facilities, and it also manages infrastructure under concession arrangements, collecting tolls or service payments over long contract periods. Its customers are mainly public authorities and other institutional clients in Spain and abroad, and the group has extended into areas such as water treatment and property development.
On this site Sacyr SA appears as a stock on the London Exchange (UK), code 0OFU, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sacyr SA (0OFU) trades on the London Exchange in UK. It last closed at EUR 4.006 on 21 October 2026.
Its price-based Market X-Ray is 49 out of 100 (a weak price profile), ranking 2,102 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 5.3% and over the last three months it fell 16.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 36 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -8.0% | ||
| From 52-week high | -18.6% | ||
| Momentum | 33 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -16.2% | ||
| 6-month return | -13.4% | ||
| 12-month return, skipping the last month | 10.0% | ||
| Stability (higher is calmer) | 71 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 25.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.5% | ||
| Liquidity | 59 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.73M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 56 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.0% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +2.5% |
|---|---|
| 1 month | −4.3% |
| 3 months | −16.2% |
| 6 months | −13.4% |
| 1 year | +5.3% |
| 3 years | +67.1% |
| 5 years | +95.7% |
Signals
| 50-day / 200-day average | 4.169 / 4.352 |
|---|---|
| Golden / death cross (60 days) | Death, 12 days ago |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.090 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Jun 2026 | EUR 0.0810 |
| 13 Jan 2026 | EUR 0.0397 |
| 27 Jun 2025 | EUR 0.0365 |
| 14 Jan 2025 | EUR 0.0632 |
| 10 Sep 2024 | EUR 0.0640 |
| 12 Jan 2024 | EUR 0.0502 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.